Opinion|Videos|September 11, 2024
Real-World Impact of SUNLIGHT Outcomes in mCRC
Medical experts discuss key takeaways from the SUNLIGHT trial, which compared FTD/TPI monotherapy to FTD/TPI plus bevacizumab for advanced metastatic colorectal cancer, including overall survival, safety, and benefits regardless of prior bevacizumab therapy, and how this data has influenced the use of FTD/TPI in the third-line setting compared with real-world outcomes.
Advertisement
Episodes in this series
- The recent SUNLIGHT trial compared FTD/TPI monotherapy to FTD/TPI in combination with bevacizumab for advanced metastatic colorectal cancer. Describe the key takeaways from this trial.
- Include in your discussion overall survival, safety profile, as well as benefit seen regardless of prior bevacizumab therapy.
- How has the SUNLIGHT data impacted your overall use of FTD/TPI in the third-line setting?
- How do the outcomes in SUNLIGHT compare with what you’ve seen as real-word outcomes?
Advertisement
Related to this article
The triple agonist also lowered HbA1C by up to 1.6% over 80 weeks, with up to 40% of participants reaching normal levels.
A network meta-analysis found vibegron outperformed mirabegron and tolterodine on several OAB efficacy measures but had higher odds of adverse events.
A US modeling study found tirzepatide and semaglutide cost-effective for MASH, while resmetirom exceeded the $100,000/QALY threshold.
Expert panel discussions covered AI and community access, chronic lymphocytic leukemia, myeloma, and breast and lung cancers.
The analysis found a nonlinear association between systemic inflammation and overactive bladder, with stronger links at higher inflammation levels.
A real-world study found that adding a GLP-1 to SGLT2 inhibitor therapy was associated with lower kidney, cardiovascular, and mortality risks in CKD.
In experiments at MD Anderson, rising CD70 helps mantle cell lymphoma evade immunity; a CD70×CD3 bispecific restores T-cell killing and prolongs survival in resistant models.
Upper-extremity synovial sarcoma required more staged surgery, while lower-extremity disease carried more complications and metastases.
Advertisement
Advertisement
Trending on AJMC
1
IRA, 340B, Medicaid: The Policy Pressures on Community Oncology
2
Drug Price Drives Value of MASH Therapies More Than Efficacy
3
Vibegron Outranks Mirabegron, Tolterodine on Several OAB Measures
4
Boston Experts Weigh Access, Sequencing, and Testing Across 4 Cancers
5